CAJ | 학술논문

目的：探讨硼替佐米联合地塞米松方案治疗多发性骨髓瘤（ MM）的临床疗效。方法选取该院诊治的51例MM 患者作为研究对象，按治疗方案分为两组，观察组31例采用硼替佐米联合地塞米松治疗，对照组20例接受长春新碱、吡柔比星、地塞米松和左旋苯丙氨酸氮芥（马法兰）治疗。比较两组患者临床疗效、不良反应等情况。结果观察组总有效率为80．65％（25／31），对照组总有效率65．00％（13／20）差异显著（ P＜0．05）；观察组对初治病例有效率为86．36％（19／22），难治复发病例有效率为66．67％（6／9）；对肾功能正常病例有效率为90．00％（18／20），对肾功能损害病例的有效率为63．64％（7／11）差异显著（P＜0．05）；观察组总不良反应发生率为51．61％，对照组为65．00％，差异显著（P＜0．05）。结论硼替佐米联合地塞米松治疗MM 有效率高，不良反应轻，对初治患者疗效最显著，值得推广应用。
목적：탐토붕체좌미연합지새미송방안치료다발성골수류（ MM）적림상료효。방법선취해원진치적51례MM 환자작위연구대상，안치료방안분위량조，관찰조31례채용붕체좌미연합지새미송치료，대조조20례접수장춘신감、필유비성、지새미송화좌선분병안산담개（마법란）치료。비교량조환자림상료효、불량반응등정황。결과관찰조총유효솔위80．65％（25／31），대조조총유효솔65．00％（13／20）차이현저（ P＜0．05）；관찰조대초치병례유효솔위86．36％（19／22），난치복발병례유효솔위66．67％（6／9）；대신공능정상병례유효솔위90．00％（18／20），대신공능손해병례적유효솔위63．64％（7／11）차이현저（P＜0．05）；관찰조총불량반응발생솔위51．61％，대조조위65．00％，차이현저（P＜0．05）。결론붕체좌미연합지새미송치료MM 유효솔고，불량반응경，대초치환자료효최현저，치득추엄응용。
Objective To investigate the efficacy and side effects of bortezomib combined with dexamethasone in the treatment of patients with multiple myeloma ( MM) .Methods 51 MM patients were divided into observation and control groups based on treatment plan . The patients in observation group (31 cases) were treated with bortezomib combined with dexamethasone and those in control group (20 ca-ses) were treated with vincristine ,pirarubicin,dexamethasone and melphalan .Efficacy and adverse reactions were observed between the two groups.Results The total efficiency in observation group and control group were 80.65% (25/31) and 65.00% (13/20),respectively (P<0.05).In observation group,the total efficiency in newly diagnosed patients and relapsed /refractory patients were 86.36%(19/22) and 66.67%(6/9),respectively.The effective rates in cases of normal renal function and in cases of renal damage were 90.00%(18/20) and 63.64% (7/11),respectively.The differences were statistically significant (P<0.05).The incidence of adverse reactions in observation group and control group were 51.61%and 65.00%,respectively(P<0.05).Conclusions Bortezomib combined with dexamethasone has a high overall response rate especially for newly diagnosed patients .And the side effects are light .It is worthily recommended in clinical appli-cation.